BioEclipse Therapeutics
PrivateLast Round
Grant
Apr 26, 2022
Total Funding Raised
$17.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
BioEclipse Therapeutics operates in Healthcare & Life Sciences and is based in Mountain View, California. Its latest recorded funding round was a Grant round in April 2022.
BioEclipse Therapeutics is a biotechnology company that develops immuno-oncology therapeutics designed to kill tumor cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioEclipse Therapeutics Comparables
Compare BioEclipse Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Calidi Biotherapeutics | 78% | |
| Genelux Corporation | 77% | |
| EpicentRx | 76% |
For institutional investors. Book with your work email.
BioEclipse Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 26, 2022 | ||||
| Crowdfunding | Jan 19, 2022 | ||||
| Series A | Jun 24, 2019 | ||||
| Seed | Jul 21, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioEclipse Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Revelis Capital Group | Series A |
| Plum Alley Investments | Series A |
| Foothill Ventures | Series A |
| California Institute for Regenerative Medicine | Grant |
| TSV Capital | Series A |
| DEFTA Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 152% MoM.
- Apr 16, 2026
Monthly visitors increased 61% MoM.
For institutional investors. Book with your work email.
BioEclipse Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioEclipse Therapeutics's valuation, stock price, and market status.
Is BioEclipse Therapeutics a public or private company?
BioEclipse Therapeutics is a private company.
What is the current stock price of BioEclipse Therapeutics?
BioEclipse Therapeutics is a private company, so its shares have no public market price. Caplight tracks BioEclipse Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioEclipse Therapeutics worth (valuation)?
Valuation information for BioEclipse Therapeutics is not publicly available.
Can I buy BioEclipse Therapeutics stock?
BioEclipse Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioEclipse Therapeutics's last funding round?
BioEclipse Therapeutics's most recent funding round was Grant on April 26, 2022.
Who are the main investors in BioEclipse Therapeutics?
Key investors in BioEclipse Therapeutics include Revelis Capital Group, California Institute for Regenerative Medicine.
Will BioEclipse Therapeutics IPO soon?
No public IPO plans have been announced for BioEclipse Therapeutics.
How can I track BioEclipse Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in BioEclipse Therapeutics's shares on secondary markets.